Meanwhile, many different mAb/CAR therapies have already entered clinics targeting various tumor biology relevant molecules even apart from the highlighted ICP axes, e.g., to interfere with neovascularization or the binding of growth factors, alone or in combination with cytokines, cell cycle/mTOR inhibitors, chemotherapeutics, etc. The gene discussed is MTOR; the disease is neoplasm.